Estrogen receptor alpha mutations regulate gene expression and cell growth in breast cancer through microRNAs.
Journal
NAR cancer
ISSN: 2632-8674
Titre abrégé: NAR Cancer
Pays: England
ID NLM: 101769553
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
received:
14
10
2022
revised:
18
04
2023
accepted:
18
05
2023
medline:
5
6
2023
pubmed:
5
6
2023
entrez:
5
6
2023
Statut:
epublish
Résumé
Estrogen receptor α (ER) mutations occur in up to 30% of metastatic ER-positive breast cancers. Recent data has shown that ER mutations impact the expression of thousands of genes not typically regulated by wildtype ER. While the majority of these altered genes can be explained by constant activity of mutant ER or genomic changes such as altered ER binding and chromatin accessibility, as much as 33% remain unexplained, indicating the potential for post-transcriptional effects. Here, we explored the role of microRNAs in mutant ER-driven gene regulation and identified several microRNAs that are dysregulated in ER mutant cells. These differentially regulated microRNAs target a significant portion of mutant-specific genes involved in key cellular processes. When the activity of microRNAs is altered using mimics or inhibitors, significant changes are observed in gene expression and cellular proliferation related to mutant ER. An in-depth evaluation of miR-301b led us to discover an important role for
Identifiants
pubmed: 37275275
doi: 10.1093/narcan/zcad027
pii: zcad027
pmc: PMC10233889
doi:
Types de publication
Journal Article
Langues
eng
Pagination
zcad027Informations de copyright
© The Author(s) 2023. Published by Oxford University Press on behalf of NAR Cancer.
Références
J Cell Mol Med. 2020 Feb;24(3):2135-2144
pubmed: 31944568
Mol Endocrinol. 1996 Nov;10(11):1388-98
pubmed: 8923465
Cancer Res. 2008 Jul 1;68(13):5004-8
pubmed: 18593897
J Steroid Biochem Mol Biol. 1994 Mar;48(4):325-36
pubmed: 8142311
Bioinformatics. 2009 Aug 15;25(16):2078-9
pubmed: 19505943
PLoS One. 2012;7(6):e38847
pubmed: 22701724
Oncol Rep. 2016 Mar;35(3):1425-32
pubmed: 26707142
J Cell Physiol. 2020 Jun;235(6):5008-5029
pubmed: 31724738
Nucleic Acids Res. 2019 Jan 8;47(D1):D155-D162
pubmed: 30423142
Front Genet. 2019 May 16;10:478
pubmed: 31156715
Cancer Res. 2008 May 15;68(10):3844-53
pubmed: 18483269
Bioinformatics. 2014 Apr 1;30(7):923-30
pubmed: 24227677
Mol Cell. 2014 Oct 2;56(1):104-15
pubmed: 25263593
Cell Mol Life Sci. 2018 Mar;75(5):939-963
pubmed: 29071385
Nucleic Acids Res. 2018 Jan 4;46(D1):D239-D245
pubmed: 29156006
Genome Res. 2009 Jan;19(1):92-105
pubmed: 18955434
Cell Physiol Biochem. 2019;52(3):382-396
pubmed: 30845378
BMC Bioinformatics. 2013 Apr 15;14:128
pubmed: 23586463
Genome Res. 2019 Sep;29(9):1429-1441
pubmed: 31362937
Biochim Biophys Acta. 2007 Aug;1773(8):1263-84
pubmed: 17126425
Int J Oral Sci. 2021 Mar 10;13(1):8
pubmed: 33692335
Genome Biol. 2014;15(12):550
pubmed: 25516281
Nat Genet. 2013 Dec;45(12):1446-51
pubmed: 24185510
Oncotarget. 2017 Jun 9;8(41):69538-69550
pubmed: 29050223
Oncogene. 2003 Sep 11;22(39):7998-8011
pubmed: 12970748
Sci Rep. 2017 Feb 06;7:41942
pubmed: 28165066
Lancet. 2005 May 14-20;365(9472):1687-717
pubmed: 15894097
J Cell Physiol. 2019 Aug;234(8):12369-12384
pubmed: 30605237
Exp Biol Med (Maywood). 2006 Mar;231(3):311-6
pubmed: 16514178
Genome Res. 2004 Oct;14(10A):1902-10
pubmed: 15364901
Trends Mol Med. 2014 Aug;20(8):460-9
pubmed: 25027972
Nat Genet. 2013 Dec;45(12):1439-45
pubmed: 24185512
Front Oncol. 2020 Jan 24;9:1473
pubmed: 32038996
Annu Rev Pathol. 2009;4:199-227
pubmed: 18817506
Cell. 2016 Apr 21;165(3):535-50
pubmed: 27104977
Mol Cancer Ther. 2014 May;13(5):1130-41
pubmed: 24634417
PLoS One. 2012;7(10):e47053
pubmed: 23056576
Endocrinology. 2019 Mar 1;160(3):536-555
pubmed: 30601996
Cancer Cell. 2018 Feb 12;33(2):173-186.e5
pubmed: 29438694
Oncogene. 2017 Apr 20;36(16):2286-2296
pubmed: 27748765
Cancer Res. 2013 Dec 1;73(23):6856-64
pubmed: 24217577
Breast Cancer Res. 2017 May 23;19(1):60
pubmed: 28535794
Nat Rev Cancer. 2018 Jun;18(6):377-388
pubmed: 29662238
Clin Cancer Res. 2014 Apr 1;20(7):1757-1767
pubmed: 24398047
Nucleic Acids Res. 2020 Jan 8;48(D1):D127-D131
pubmed: 31504780
Cancer Discov. 2017 Mar;7(3):277-287
pubmed: 27986707
Elife. 2016 Feb 02;5:
pubmed: 26836308
Cancer Res. 1997 Apr 1;57(7):1244-9
pubmed: 9102207
Nat Rev Genet. 2011 Feb;12(2):99-110
pubmed: 21245828
Genome Res. 2015 Sep;25(9):1401-9
pubmed: 26290535
Proc Natl Acad Sci U S A. 2009 Sep 15;106(37):15732-7
pubmed: 19706389
Target Oncol. 2020 Jun;15(3):261-278
pubmed: 32451752
Cancer Res. 2022 Apr 1;82(7):1321-1339
pubmed: 35078818
Nat Commun. 2021 Aug 24;12(1):5086
pubmed: 34429404
Lancet. 1998 May 16;351(9114):1451-67
pubmed: 9605801
Cancer Res. 2011 Apr 15;71(8):2926-37
pubmed: 21393507
Annu Rev Med. 2009;60:167-79
pubmed: 19630570
Nat Methods. 2015 Apr;12(4):357-60
pubmed: 25751142
Oncogene. 2012 Dec 13;31(50):5162-71
pubmed: 22286770
Cancer Res. 2021 Feb 1;81(3):732-746
pubmed: 33184106
J Biochem Mol Toxicol. 2021 Feb;35(2):e22650
pubmed: 33063403
J Biol Chem. 2014 Feb 7;289(6):3138-47
pubmed: 24337579
Mol Cancer Res. 2023 Jun 26;:
pubmed: 37363949
Annu Rev Pathol. 2014;9:287-314
pubmed: 24079833
Mol Cancer Ther. 2015 Jun;14(6):1306-16
pubmed: 25852060
Lancet. 2011 Aug 27;378(9793):771-84
pubmed: 21802721
Cancer Res. 2021 Feb 1;81(3):539-551
pubmed: 33184109
Curr Genomics. 2009 May;10(3):169-83
pubmed: 19881910
Elife. 2015 Aug 12;4:
pubmed: 26267216